Karthaus, Meinolf
Heinemann, Volker
Riera-Knorrenschild, Jorge
Kretzschmar, Albrecht
Welslau, Manfred
Kaiser, Ulrich
Pelz, Henning
Ettrich, Thomas J.
Held, Swantje
Kehmann, Linde
Hess, Jürgen
Reisländer, Timo
Weiss, Lena
,
Article History
Received: 6 September 2023
Accepted: 3 July 2024
First Online: 23 July 2024
Declarations
:
: This study was conducted in accordance with the principles of the Declaration of Helsinki and with the International Council on Harmonisation guideline for good clinical practice. The protocol was approved by the ethics committee of the Medical Faculty of the Ludwig-Maximilians-University, Munich, (reference number: 17–429). All patients provided written informed consent prior to entering the trial.
: Not applicable.
: MK reports receiving fees for serving on advisory boards and travel support from Servier. VH reports receiving fees for talks and advisory board roles from Merck, Amgen, Roche, Sanofi, Servier, Pfizer, Pierre-Fabre, AstraZeneca, BMS; MSD, Novartis, Terumo, Oncosil, NORDIC, Seagen, GSK and for receiving research funding from Merck, Amgen, Roche, Sanofi, Boehringer-Ingelheim, SIRTEX, Servier. AK reports receiving fees for serving on advisory boards for Servier. MW reports receiving fees for serving on advisory boards from Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead, Hexal, Janssen, Lilly, Medac, Novartis, Roche and SANOFI. TJE reports receiving grants and personal fees from AstraZeneca, Bayer, BMS, Daiichi Sankyo, Eisai, Incyte, Ipsen, Lilly, Merck Serono, MSD, Pierre Fabre, Roche, Sanofi, Servier. LK, JH and TR report being employees of Servier Deutschland GmbH. LW reports receiving honoraria from Roche and Servier as well as travel support from AMGEN. No other conflict of interest relevant to this article was reported.